Breast cancer drug cuts risk of most common form returning by 25%
Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantlyThousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them …